Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - Spanish Language: Video #27 Potential Side Effects of Immune Checkpoint Inhibitors and Basic Management Approaches
Author
Luis Raez, MD FACP FCCP
 

Posibles efectos secundarios de los inhibidores de puntos de control inmunológicos y los enfoques básicos de manejo

Possible side effects of the immunological checkpoint inhibitors and the basic management approach

 

 Dr. Luis Raez, MD FACP FCCP,

Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute,

Clinical Associate Professor of Medicine, Florida International University

 

Spanish TRANSCRIPT

La inmunoterapia, en general, no es muy tóxica. Muchas veces cuando los pacientes hablan con nosotros, se asustan porque uno le da la lista de todos los efectos secundarios que potencialmente puede tener, pero en general, en base a los estudios clínicos y a la realidad, la inmunoterapia es mucho menos tóxica. La incidencia de efectos secundarios graves es menor y los pacientes la toleran mucho mejor.

La inmunoterapia da efectos secundarios clásicos, como todos los causados por agentes contra el cancer, como fatiga (muy común) o sarpullido en piel. Los que son particulares son interesantes, como hipertiroidismo o mayormente hipotiroidismo, que muchas veces es asintomático por lo que muchas veces no vamos a esperar que un paciente venga con exceso de peso o somnolencia, por lo que tenemos que estar constanmente checándole la sangre para que descubramos el hipotiroidismo y actuar antes de que el paciente lo haga clínico. Aún no hay un consenso, pero muchos de nosotros cada 6 semanas checamos el TSH como un tamizaje para ver si el paciente está desarrollando hipotiroidismo o no.

Los efectos secundarios graves que todos le tienen miedo como la neumonitis o la colitis son muy poco comunes, pero aun así tenemos que estar despiertos y en alerta. Si el paciente experimenta alguno de esos, inmediatamente se tiene que poner al paciente en esteroides para combatir estos efectos secundarios y después descontinuar el medicamento.


 

English TRANSCRIPT

Immunotherapy, in general, is not very toxic. Many times when the patients talk with us, they are scared because we give them the list of the possible side effects of the therapy based on clinical trials. In reality, immunotherapy is less toxic. The severe side effects incidence is lower and patients overall tolerate it better.

Immunotherapy has classic side effects like in any other cancer agent like fatigue or a skin rash. The ones that are particularly interesting like hyperthyroidism or hypothyroidism which are mainly asymptomatic, are interesting because we are not expecting a patient with weight gain or somnolence, so we have to be constantly checking their blood to discover any possible hypothyroidism and treat it before it’s clinical. There isn’t a consensus yet, but most of us check every six weeks the TSH to see if the patient is developing hypothyroidism or not.

The severe side effects that everyone is afraid of are pneumonitis or colitis, even though they are uncommon, we have to be in alert for any possible sign. If the patient has one of them, we will have to give him immediately steroids to fight those side effects and then continue with the treatment.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Head And Neck Cancer Program
Video
Drs. Shetal Patel, Siddharth Sheth, and Jared Weiss discuss the most recent advances in head and neck cancer treatment, including curable and incurable head and neck cancers, thyroid cancers, and HPV positive and negative cancers.  
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Puneeth Iyengar discusses using radiation therapy in metastatic lung cancer, advances in Oligometastatic disease, (SBRT) for Oligoprogressive, The NRG-LU Trial, and future goals of metastatic NSCLC Treatment.  To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Lyudmila Bazhenova talks about Antibody Drug Conjugates, Toxicities in Antibody Drug Conjugate Treatment, and Bispecific Antibodies in Lung Cancer.  To watch the complete playlist click here.

Forum Discussions

Hello and welcome to Grace.  I'm sorry you're worrying about this but it probably isn't cancer. 

 

From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...

I wanted to share this post with others in your same situation.  This post from Dr. West is the same one I shared in our PM and can hopefully reasure you...

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

Recent Comments

JOIN THE CONVERSATION
Tagrisso is the latest drug…
By JanineT GRACE … on
4th generation of EGFR
By happybluesun on
(At least for the carnivores…
By JanineT GRACE … on
Yes, it is a relief. There…
By blaze100 on